Brian Windsor
President and COO,
Aileron Therapeutics
United States
Brian Windsor, Ph.D. has served as the President and Chief Operating Officer of Aileron since October 2023. Prior to
becoming president and chief operating officer, Dr. Windsor served, since July 2013, as President, Chief
Executive Officer and a Director of Lung Therapeutics. From September 2019 to March 2022, Dr. Windsor served as a Director
and the Chief Science Officer of TFF Pharmaceuticals, Inc., a public biopharmaceutical company that Lung spun
out into an independent company. From January 2018 to March 2022, Dr. Windsor provided consulting services
to TFF Pharmaceuticals, Inc. in the areas of science and technology. From November 2009 to March 2013,
Dr. Windsor served as president of Enavail, LLC, a specialty pharmaceutical manufacturing company, where he
oversaw all aspects of the company’s pharmaceutical drug development. Before joining Enavail, Dr. Windsor
directed portfolio company management for Emergent Technologies, Inc., an early stage technology venture
creation and management company, where he served as managing director or president for ten portfolio
companies. Dr. Windsor holds a B.S. and a Ph.D. in molecular biology from The University of Texas at Austin.
Sessions
-
26-Feb-2024Aileron Therapeutics
)
){kind=logo}
)
){kind=logo}
){kind=logo}